Dual Ig domain-containing adhesion molecule (DICAM), a protein with homology to the junctional adhesion molecule family, has been demonstrated to interact with integrin aVb3 that plays a critical role in angiogenesis. Here, we determined the role of DICAM during angiogenesis and the molecular mechanisms involved in the inhibition of angiogenesis.
Introduction
Angiogenesis, the formation of new blood vessels from pre-existing vessels, plays a central role in organ development and in a variety of pathological conditions such as tumour growth, ocular disease, and inflammatory arthritis. 1 Angiogenesis initiates when hypoxic, diseased, or injured tissues release angiogenic factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor. 2 These factors stimulate the migration and proliferation of existing endothelial cells in vessels, which lead the formation of capillary tubes and the recruitment of other cell types to generate and stabilize new blood vessels. 2 Cell adhesion molecules, together with soluble angiogenic factors, are also critical for angiogenesis, and facilitate cell-to-cell interactions and endothelial cell proliferation, migration, and survival by interacting with the extracellular matrix (ECM). 2 The integrin family, the primary cell surface receptors for the ECM, mediates the interactions of endothelial cells in newly formed 'sprouts', by adhering to one another and to the ECM. 3 In particular, integrin aVb3 is an essential player during angiogenesis, and was the first adhesion receptor to be characterized as a marker of angiogenic blood vessels. 4 Quiescent endothelial cells express little or no integrin aVb3 on their cell surfaces, but exposure to inflammatory cytokines, like tumour necrosis factor-a, leads to a dramatic increase in the surface expression of integrin aVb3 on newly formed blood vessels. 5 Integrin aVb3 is a receptor for a plethora of matrix proteins, such as vitronectin, fibronectin, von Willebrand's factor, Del1, angiopoietin-like protein 3, CYR61, thrombin, lactadherin, and osteopontin. 6 -12 These various matrix components released from tumours or inflammatory tissues are bound by integrin aVb3 and provide a supportive scaffold that facilitates endothelial cell adhesion, migration, and invasion, and to the enhancement of angiogenesis. In addition to integrin, several adhesion molecules expressed on endothelial cells also contribute to angiogenesis from its initiation to vessel maturation. 2 Adhesion molecules, such as platelet endothelial cell adhesion molecule (PECAM), junctional adhesion molecule (JAM) -A, and intercellular adhesion molecule 2, support endothelial cell -cell interactions, and are involved in regulating endothelial homeostasis and angiogenesis. 13 -17 However, despite the substantial progress made in our understanding of the mechanisms of angiogenesis, the mechanisms responsible for the involvements of adhesion molecules in angiogenesis are poorly understood. We recently identified a new adhesion molecule, dual Ig domain-containing adhesion molecule (DICAM), which is ubiquitously expresses in various organs and cells, including endothelial cells. 18, 19 Functionally, DICAM is involved in cell-to-cell adhesion via a heterophilic interaction with integrin aVb3. 18, 19 Its phylogenic similarity with JAM family and its propensity to interact with integrin aVb3 suggest that DICAM may participate in endothelial cell adhesion and migration, and consequently in the regulation of angiogenesis. In this study, we investigated the role of DICAM during angiogenesis and the mechanisms involved in the inhibition of angiogenesis.
Methods

Antibodies and reagents
Anti-DICAM polyclonal antibody was developed by immunizing rabbits with recombinant DICAM protein, as described previously. 19 Rabbit poly-
Bax, Bcl-2, Caspase-3, and CD31 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies for p-b3 (pY773) were from Invitrogen (Carlsbad, CA, USA), for cleaved caspase-8 from Santa Cruz biotechnology (sc-5263; Santa Cruz, CA, USA), and for ERK1/2 from BD Biosciences (San Jose, CA, USA). Mouse monoclonal antibody for integrin aVb3 was from Millipore (Bilerica, MA, USA) and for b-actin from Sigma-Aldrich (St Louis, MO, USA), and human recombinant VEGF-A was from PeproTech (Rochy Hill, NJ, USA).
Isolation of human umbilical vein vascular endothelial cells
Primary human umbilical vein vascular endothelial cells (HUVECs) were obtained from normal, healthy, and full-term deliveries with maternal informed consent. The study protocol (10-H-0012) was approved beforehand by the Daegu Fatima Hospital Institutional Review Board and the regional board of the Ethics Committee. This study conforms to the principles outlined in the Declaration of Helsinki for the use of human tissue. HUVECs were isolated using 0.2% collagenase type 2 (LS004177, Worthington Biochemical, Lakewood, NJ, USA) from human umbilical cord veins, and were maintained in endothelial growth medium-2 containing 10% foetal calf serum and penicillin (100 U/mL) and streptomycin (100 mg/mL) at 378C in a humidified 5% CO 2 atmosphere. Passages 1 -4 were used for experiments. M199 media containing 1% foetal bovine serum (FBS) were used to starve and stimulate HUVECs.
Transduction of adenovirus expressing DICAM and DICAM shRNA into HUVECs
Recombinant adenovirus (Ad) expressing full-length DICAM (Ad-DICAM) or b-galactosidase (Ad-LacZ) was prepared as described previously. 20 HUVECs were plated in 60 mm dishes and when 70% confluent were infected with 50 or 100 m.o.i. of viral particles in 2 mL of serum-free M199 medium for 5 h. Growth medium (2 mL) was then added, and cells were incubated for additional 24 h before being evaluated. 
Immunoblotting, subcellular fractionation, and in situ immunofluorescent staining
To assess the expressions of DICAM and signalling proteins related to VEGF or vitronectin-mediated pathways, western blot analysis was performed using total HUVECs lysates, as described previously. 21 Briefly, after SDS -polyacrylamide gel electrophoresis, proteins were transferred to polyvinylidene fluoride membranes and blocked with 5% skim milk at room temperature (RT) for at least 1 h. VEGF or vitronectin-mediated signalling proteins and DICAM were then detected using specific antibodies.
After binding with horseradish peroxidase-conjugated secondary antibodies, the blots were visualized with enhanced chemiluminescence solution (Amersham Biosciences, Buckinghamshire, UK) and developed. The localization of DICAM and integrin aVb3 was further investigated using the subcellular protein fractionation kit (Thermo scientific, catalog no.78840) according to the manufacturer's protocol. Briefly, HUVECs were harvested by trypsin, washed in PBS, resuspended in cytoplasmic extraction buffer, incubated at 48C for 10 min with gentle mixing, and then centrifuged at 3000 g for 5 min. The supernatant containing cytoplasmic extract was collected. Then serial buffers containing proteases for membrane extraction, nuclear extraction, and cytoskeletal extraction were added to the pellet, incubated and then centrifuged. Through repeated procedures, the supernatant containing membrane, nuclear, and cytoskeletal extract were collected sequentially. The extracted subcellular lysates were subjected to western blot analysis.
To further determine the localization of DICAM and integrin aVb3, immunofluorescent staining of HUVECs was conducted with or without VEGF treatment for the indicated times, as described previously. 18 
In vitro Matrigel tube formation and in vivo Matrigel plug assay
For the tube formation assay, 96-well plates were coated with Matrigel (100 mL, BD Matrigel TM ) and allowed to polymerize at 378C for 30 min. Transfected HUVECs (Ad-LacZ, Ad-DICAM, shRNA-Control, and shRNA-DICAM) were suspended in M199 medium at a density of 2.5 × 10 5 cells/mL, respectively, and 100 mL of this cell suspension was added and incubated at 378C with 5% CO 2 for 18 h. Total tube formation was counted at a magnification ×10 using a Nikon stereoscopic zoom microscope (model SMZ745T).
In vivo Matrigel plug assays were performed to confirm in vitro tube formation results. Briefly, after anaesthetizing 8-week-old C57BL/6 mice with avertin (2-2-2 tribromoethanol, Sigma-Aldrich; 240 mg/kg, ip), Matrigels premixed with 2.5 × 10 8 p.f.u. of Ad-Lacz or Ad-DICAM in the presence or absence of VEGF (20 ng/mL) was injected sc above the flank region. Adequacy of anaesthesia was monitored by pedal withdrawal reflex before Matrigel injection. Animals were sacrificed with the cervical dislocation method 14 days later, and Matrigel plugs were harvested, fixed, and paraffin embedded. Sections were immunohistochemically stained with anti-CD31 antibody, and CD31-positive microvessels were counted in 10 randomly selected microscopic fields (×100) by three independent individuals. This study conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011).
In vitro wound healing assay and Transwell migration assay
To examine wound healing assay, HUVECs transfected with Ad-Lacz or Ad-DICAM (100 m.o.i.) were cultured in six-well plates with or without a vitronectin coating. When cells were confluent, a single straight scratch was made in centers of cell monolayers using a sterile pipette tip. After removing debris, cells were cultured in serum-free medium in the presence or absence of VEGF (20 ng/mL) for 24 h. Photographs were then taken of each well, and wound thicknesses were measured.
To analyse the Transwell migratory activity of HUVECs, the Transwell filters (8 mm pore size) were coated with vitronectin. HUVECs (5 × 10 5 cells) in 200 mL 1% M199 media were added to the chamber, and the chamber was then placed in a 24-well plate containing 1% medium with or without VEGF 20 ng/mL. Cells were incubated for 24 h at 378C in 5% CO 2 . Non-migrated cells were scraped from the upper surface of the membrane with a cotton swab. Cells on the underside of Transwell filters were stained with Diff-Quick solution, and then photographed and quantified.
Apoptosis assay
HUVECs transfected with Ad-DICAM or Ad-LacZ were cultured in serum-free M199 media for 24 h. Adherent cells were harvested by trypsinization, washed with warm PBS, and 1 × 10 5 cells were then incubated with FITC-conjugated Annexin V in a buffer-containing propidium iodide at RT for 15 min (apoptosis detection kit, BD Bioscience Pharmingen TM , San Deigo, CA, USA). Finally, Annexin V and/or propidium iodide stained cells were counted using a flow cytometry (FACS) unit (Aria II; BD Bioscience, Franklin Lakes, NJ, USA).
Statistical analysis
The analysis was performed using Student's t-test. All data are presented as means + SD of means. P-values ,0.01 or 0.05, as specifically indicated in the legends, were considered statistically significant.
Results
DICAM was expressed on the endothelial cells of large vessels to small capillaries
To investigate DICAM expression on human endothelial cells, left internal mammary artery (LIMA) tissues were examined immunohistochemically. DICAM was identified in intimal-lining endothelial cells and on smooth muscle cells of the media in LIMA tissues ( Figure 1A and B). DICAM was also observed in endothelial cells of the vasa vasorum in the adventitia ( Figure 1C ). These observations indicate that DICAM is widely expressed on endothelial cells from large vessels to small capillaries. At the single-cell level, immunofluorescent staining showed that DICAM was supposed to be mainly distributed in the cytoplasm and the perinuclear area of HUVECs ( Figure 1D) . To investigate the exact localization of DICAM in HUVECs, we further analysed DICAM localization with biochemical subcellular fractionation. As shown in Figure 1E , DICAM was mainly detected at the fractions of membrane and soluble nucleus and it was negligible in cytoplasmic fraction. In the presence of 20 ng/mL VEGF, the membrane fraction of DICAM was increased, but the nucleus fraction was not ( Figure 1E ).
DICAM was up-regulated by VEGF and vitronectin via the MEK/ERK and PI3K/AKT pathways
Based on our observations of DICAM expression in HUVECs, we investigated whether VEGF modulates DICAM expression in HUVECs. As illustrated in Figure 2A , it was found that VEGF dosedependently increased DICAM expression in HUVECs. When HUVECs were treated with 20 ng/mL of VEGF, DICAM expression was increased from 1 h later by VEGF, which was maintained until 8 h ( Figure 2B ). We then sought to identify the signalling pathways down-stream of VEGF involved in the regulation of DICAM expression. It is known that the MEK/ERK and PI3K/AKT pathways are the major signalling pathways of VEGF receptor 2. 22 Accordingly, HUVECs were seeded on vitronectin coated or non-coated plastic plates with or without 20 ng/mL VEGF and incubated for 4 h with 50 mM of PD98059 or LY293002 that is MEK1 and PI3K inhibitors, respectively. HUVECs cultured on vitronectin, the ligand of integrin aVb3, showed a marginal increased DICAM expression compared with controls, but the effect of VEGF on DICAM expression was more potent than vitronectin. Combined treatment of vitronectin with VEGF had no additive effect on DICAM expression, suggesting a common signalling pathway between VEGF and integrin aVb3 pathways with respect to DICAM expression. When cells were treated with PD98059 (MEK1 inhibitor), DICAM expression induced by vitronectin and VEGF was significantly decreased. In addition, LY294002 (PI3K inhibitor) had a potent suppressive effect on DICAM expression. The co-treatment of both inhibitors strongly blocked DICAM induction in vitronectin alone or vitronectin/VEGF condition, but it was less suppressive in VEGF alone condition ( Figure 2C ). These results indicate that VEGF and vitronectin regulate DICAM expression through in part the activation of ERK and AKT pathways.
DICAM inhibited angiogenesis in capillary tube formation and Matrigel plug assays
To verify the effect of DICAM on angiogenesis, gain-or loss-offunction experiments were performed based on capillary tube formation by HUVECs. The efficiency of Ad and sh-RNA transfection was determined using RT-PCR ( Figure 3A ). HUVECs transduced with Ad-DICAM or Ad-Lacz were seeded on VEGF-containing Matrigelcoated plates and then incubated for 24 h. DICAM-transduced HUVECs exhibited poor capillary tube formation, and numbers of branch points decreased by 52.5% when compared with Ad-LacZ (P , 0.001, Figure 3B , upper panel). As was expected, HUVECs transduced with DICAM-shRNA exhibited a more extensive capillary network than HUVECs transduced with control-shRNA ( Figure 3B , lower panel). Next, the inhibitory effects of DICAM on angiogenesis were confirmed using an in vivo Matrigel plug assay. Mixed solutions (500 mL) containing 2.5 × 10 8 p.f.u. of Ad expressing DICAM or LacZ and 250 mL of Matrigel with or without 20 ng/mL VEGF were injected s.c. above a flank of mice. Fourteen days later, Matrigel plugs were excised and vessel formation was analysed. Grossly, Matrigel plugs mixed with Ad-DICAM exhibited markedly less vascularization than mock virus regardless of the presence of VEGF ( Figure 3C ). Microscopic examination in low-power fields revealed that the counts of CD31 + vessels in Matrigel plugs mixed with Ad-DICAM were 79.4% lower in the presence of VEGF and 61.9% lower in the absence of VEGF when compared with Ad-LacZ ( Figure 3D and E). Taken together, these findings show that DICAM inhibits angiogenesis in vitro and in vivo conditions.
DICAM attenuated HUVEC migration
Because cell migration plays a central role during angiogenesis, the motilities of HUVECs infected with Ad-LacZ or Ad-DICAM were evaluated using a wound healing assay. HUVECs were grown to confluence on vitronectin-coated or non-coated plates, and wounds were made in cell monolayers. Cells were then cultured in 1% M199 media for 24 h. Forced DICAM expression was found to strongly inhibit wound closure regardless of the presence of vitronectin ( Figure 4A  and B) . We then performed the Transwell migration assay to exclude the proliferation effect of DICAM in the wound healing assay and to investigate the role in chemotactic migration. HUVECs were plated at upper chamber and incubated for 24 h with or without VEGF gradient. In accord with the result of the wound healing assay, the Transwell migration assay showed that DICAM-transfected HUVECs less migrated through the Transwell pore than LacZ-transfected cells ( Figure 4C and D) .
DICAM increased HUVEC apoptosis without influencing proliferation
We further investigated the effects of DICAM on HUVEC proliferation and apoptosis. HUVECs (1 × 10 4 ) transfected with Ad-LacZ or Ad-DICAM were seeded on 96-well plates after FBS starvation. The MTT assay showed that HUVEC viability was not affected by DICAM overexpression regardless of the presence of VEGF or vitronectin (Supplementary material online, Figure S1A) . Moreover, the BrdU incorporation assay also revealed that DICAM did not attenuate HUVEC proliferation (Supplementary material online, Figure S1B ).
The influence of DICAM on HUVECs apoptosis was then assessed with respect to integrin activity. HUVECs were cultured in serum-free M199 media without any stimulation for 24 h, and then assessed for apoptosis by flow cytometry. As shown in Figure 5A and B, DICAM promoted an early and late apoptosis of HUVECs regardless of integrin ligand. To elucidate the molecular mechanism of DICAM-mediated apoptosis, we examined whether DICAM affects the activation of caspase-8 and the expressions of Bax and Bcl-2, markers of extrinsic and intrinsic death signals, respectively. In accordance with FACS results, DICAM transfection attenuated the expression of Bcl-2 in HUVECs, and this attenuation was not affected by the presence of integrin ligand. Interestingly, although the presence of integrin ligand did not influence the apoptosis of HUVECs, DICAM increased the level of the 36 kDa cleaved caspase-8 in vitronectin-coated condition ( Figure 5C ). This result suggests a possibility that DICAM may play a role in extrinsic apoptosis pathway as well.
The forced expression of DICAM attenuated vitronectin-mediated integrin aVb3/FAK signalling
In a previous study, we found that DICAM interacts directly with integrin aVb3 and shows cross-talk with M-CSF signalling, which suggests its possible involvement with VEGF signalling during angiogenesis. 18 Accordingly, we examined whether the forced expression of DICAM affects VEGF and/or integrin aVb3 signalling to investigate the mechanism responsible for the DICAM-mediated inhibition of angiogenesis. After overnight serum starvation, DICAM-transfected HUVECs were stimulated with 20 ng/mL of VEGF. These DICAMtransfected HUVECs showed more VEGFR2 phosphorylation than mock transfected cells, whereas Src has no significant change by the presence of DICAM. Overexpression of DICAM suppressed the VEGF-induced phosphorylation of AKT and p38 MAP kinase. Other signalling pathways including integrin b3, FAK, ERK1/2, and JNK were not influenced by DICAM ( Figure 6A ). We then assessed whether vitronectin-induced integrin activation was affected by DICAM ( Figure 6B ). Serum starved HUVECs were detached using EDTA without trypsin to prevent the loss of cellsurface proteins, and then seeded on vitronectin-coated plates. Vitronectin stimulation increased the phosphorylation of integrin b3 in 15 min, whereas the forced expression of DICAM delayed integrin b3 activation, but increased total integrin b3, implying the presence of a feedback mechanism ( Figure 6B) . In addition to the delayed activation of integrin b3, DICAM attenuated the phosphorylation of FAK, a key component of integrin signal transduction. The basal activity of Src was increased by overexpression of DICAM. However, vitronectin-mediated increase in Src phosphorylation was higher in Ad-LacZ transfected HUVECs than Ad-DICAM. Importantly, the forced expression of DICAM also abrogated the activation of AKT. Furthermore, DICAM transduction attenuated the phosphorylations of p38, but did not influence the phosphorylation of ERK1/2 and JNK kinases.
Based on the finding of DICAM-mediated inhibition of integrin aVb3 signalling, we examined whether DICAM co-localized with integrin aVb3 by in situ immunofluorescent staining. Without VEGF, DICAM co-localized with integrin aVb3 only in the perinuclear area of HUVECs, but co-localization of DICAM and integrin aVb3 was enhanced by VEGF, which suggested a close association between DICAM and integrin aVb3 in the presence of VEGF ( Figure 6C) . Taken together, these findings demonstrate that the anti-angiogenic effect of DICAM on HUVECs is associated in part with the inhibition of integrin aVb3 signalling.
Discussion
The present study was conducted to determine the function of DICAM during angiogenesis, based on the knowledge that DICAM directly interacts with integrin b3 and disrupts its function. 18 In this study, we found that DICAM is an important negative regulatory molecule during angiogenesis and that it achieves this by attenuating the activation of AKT and p38 MAP kinase in VEGF-VEGFR2 and vitronectin-integrin signalling. Furthermore, DICAM was found to be dose-and time-dependently induced by VEGF. These findings suggest that DICAM is a novel anti-angiogenic component through the attenuation of AKT and p38 MAP kinases activation. Quiescent endothelial cells express hardly any integrin aVb3.
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However, integrin aVb3 is dramatically up-regulated on the endothelial cells of newly formed blood vessels and plays a critical role during angiogenesis. 4 Nevertheless, the mechanisms responsible for regulating integrin aVb3 function during angiogenesis are poorly understood. The present study shows that DICAM has a suppressive effect on b3 integrin and FAK activation, and these are accompanied by the attenuation of their down-stream signalling, AKT and p38 MAP kinase. These findings concur with those of our previous study, in which DICAM was found to inhibit integrin aVb3 signalling during osteoclastogenesis. 18 In our previously study, direct interaction between DICAM with integrin b3 attenuated heterodimerization between integrin aV and b3, which perturbed integrin-ligand interactions and the outside-in signalling of integrin b3. 18 In addition, treatment with the extracellular domain of DICAM suppressed osteoclast differentiation, 18 which suggests that the DICAM-mediated suppression of integrin aVb3 signalling is mediated by the inhibition of ligand interactions at the extracellular level. In this manner, the increased expression of DICAM by VEGF can potentially attenuate integrin aVb3
signalling. In the present study, DICAM was found to suppress vitronectin-mediated phosphorylation of integrin b3, which provides a novel endogenous negative regulation of integrin aVb3 signalling during angiogenesis. Interestingly, when HUVECs were stimulated with VEGF, VEGFR2 phosphorylation was increased by the forced expression of DICAM. Several lines of evidences showed that VEGFR2 and integrin aVb3 act synergistically during angiogenesis. Functionally, ligand-induced integrin aVb3 activation enhances the phosphorylation of VEGFR2, 23 and in turn, treatment with VEGF induces the formation of integrin aVb3 -VEGFR2 complex and activates integrin aVb3 via Src kinase. 24 In addition to this synergistic effect, VEGFR2 has a compensatory effect when integrin b 3 is functionally perturbed. Actually, integrin b 3 null mice exhibited enhanced pathological angiogenesis, and this was responsible for compensatory increases in the expression and function of VEGFR2. 25, 26 These results together with ours suggest a compensatory enhanced-VEGFR2 signalling when integrin b3 is functionally disrupted. It is interesting to point out that the phosphorylations of AKT and p38 MAP kinase were attenuated in both integrin and VEGFR2 stimulation. Considering that the activity of Src was not significantly changed by DICAM, these results suggest the possible involvements of other common intracellular mediator between integrin and VEGFR2 signalling. One of candidate signalling mediator is integrin-linked kinase (ILK). In fact, VEGF can trigger AKT phosphorylation in an ILK-dependent manner, 27 and recent evidence showed that knockdown of ILK suppressed VEGF-induced p38 MAP kinase and AKT phosphorylation, but had no effects on VEGFR2, JNK, or ERK1/2 phosphorylation, which are exactly same with our results. 28 As a downstream target of N-Ras, PI3K also mediates synergism between VEGF and integrin aVb3. 29 Considering that AKT mainly activated by PI3K
was dramatically attenuated by DICAM, Ras-PI3K can be a target signalling molecule of DICAM-mediated inhibition of AKT and P38 MAP kinase. Interaction of DICAM with other intracellular mediators such as ILK or PI3K needs to be investigated in further study.
In the present study, we found that DICAM increased HUVEC apoptosis and it was associated with the attenuation of Bcl-2 expression regardless of the presence of vitronectin, a ligand of integrin aVb3. Although the precise mechanism of Bcl-2 suppression by DICAM was not fully elucidated in the present study, we suggest that it could be the result of the suppression of AKT and p38 MAP kinase signalling ( Figure 5 ). It is well established that AKT is a cell survival signal that stimulates Bcl-2 protein expression. 30 Furthermore, recent study revealed that p38 MAP kinase increased the hypoxia induced expression of Bcl-2 in endothelial cells. 31 These evidences strongly suggest that the attenuation of AKT and p38 MAP kinase signalling by DICAM may be responsible for the reduced expression of Bcl-2. In addition to Bcl-2-related intrinsic apoptosis pathway, we showed here that DICAM overexpression increased the cleaved active caspase-8 in the presence of vitronectin even though the apoptosis on FACS result was not increased in the vitronectin condition. This discrepancy can result from the dominance of mitochondrial apoptosis pathway in the serum-deprived HUVEC apoptosis, 32 which may mask the effect of DICAM-mediated activation of caspase-8. Taken together, DICAM could be a potent pro-apoptotic molecule that activates both the intrinsic and extrinsic integrin-dependent apoptotic pathways, which suggests its possible use as a therapeutic target, especially in cancer and chronic inflammatory diseases. Phylogenic analysis has revealed that DICAM belongs to the CTX protein family, which is divided into three groups, namely the CTX, JAM, and CAR groups. DICAM has more homology with the JAM group than the other two, 19 and the JAM protein family has several subgroups, namely JAM-A, -B, -C, JAM-4, and JAML. JAM-A has been shown to co-precipitate with integrin aVb3-like DICAM, but its role in angiogenesis is the opposite of that of DICAM, as it enhances the migration of HUVECs by increasing integrin signalling. 14, 33, 34 In addition, JAM-C as its soluble form stimulates endothelial cell migration through a Src, p38, and PI3K-dependent pathways. 15, 35 DICAM is the first member of the CTX family found to inhibit VEGF-mediated angiogenesis by attenuating AKT and p38 MAP kinase signalling. In addition to their effects on cell-to-cell interactions, adhesion molecules provide diverse molecular signals that impact normal and pathological angiogenesis, which suggests that DICAM be considered a candidate for the treatment of pathological angiogenesis.
In conclusion, DICAM induced by VEGF was found to suppress angiogenesis by attenuating endothelial cell migration and to increase integrin-mediated apoptosis by suppressing AKT and p38 MAP kinase signalling ( Figure 6D) . These results suggest that DICAM acts as a negative regulator of angiogenesis, and that it should be considered a potential therapeutic target for various pathological conditions in which angiogenesis plays a major role.
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